Health Canada recently conducted a safety review and found there may be a link between the use of bacitracin for injection products and the risk of nephrotoxicity and hypersensitivity, including allergic contact dermatitis and/or anaphylaxis. Cases of nephrotoxicity and serious hypersensitivity, including allergic contact dermatitis and/or anaphylaxis, have also been reported when these products are used outside of their authorized indications. Health Canada is working with the manufacturers to update the Canadian Product Monographs for all bacitracin for injection products to further strengthen the information about nephrotoxicity and to include information about anaphylactic reactions.
Products affected
|
Brand/Product Name |
Dosage Form and Strength |
Manufacturer |
Drug Identification Number (DIN) |
|
BACIJECT |
Powder for Solution, 50,000 IU/ vial |
SteriMax Inc. |
02245571 |
|
BACITRACIN USP |
Powder for Solution, 50,000 IU/ vial |
Pfizer Canada ULC |
00030708 |
|
BACITRACIN FOR INJECTION* |
Powder for Solution, 50,000 IU/ vial |
Fresenius Kabi Canada Ltd. |
02255820 |
|
BACITRACIN FOR INJECTION, USP* |
Powder for Solution, 50,000 IU/ vial |
Auro Pharma Inc. |
02491109 |
*This product has been authorized for sale, but it is not marketed in Canada at this time.
Background information
Bacitracin for injection products are indicated for intramuscular use in the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug.
Bacitracin solutions, applied locally in the form of compresses or instillations, may be used once or twice daily in secondarily infected wounds, ulcers, pyodermas and other superficial skin infections and in superficial infections of the eye caused by bacitracin-susceptible organisms. Bacitracin solutions may be instilled into the nasal cavities or administered by inhalation as an aerosol in the treatment of bacitracin-susceptible infections of the upper and lower respiratory tract. In severe or extensive infections, appropriate antibacterial therapy should be given in addition to local treatment with bacitracin.
Health Canada conducted a safety review and concluded that there may be a link between the use of bacitracin for injection products and the risk of nephrotoxicity and serious hypersensitivity, including allergic contact dermatitis and/or anaphylaxis. This safety review was triggered by the
United States Food and Drug Administration (U.S. FDA) Drug Safety Communication dated January 31, 2020. In that communication, the FDA requested all current U.S. manufacturers of bacitracin for injection to voluntarily withdraw their product from the U.S. market. The FDA review determined that U.S. healthcare professionals no longer use bacitracin for injection, and considered the availability of other approved, effective treatments that do not have the same serious risks, including nephrotoxicity and anaphylactic reactions. Health Canada’s review did not include non-prescription bacitracin-containing products marketed as ointments since no safety concerns for these products were identified in the U.S. FDA’s Drug Safety Communication.
Bacitracin for injection products are now contraindicated in patients with impaired renal function, including those taking nephrotoxic drugs.
To further minimize risks in Canada, Health Canada, in collaboration with the manufacturers of bacitracin for injection products, will update the
Contraindications, Warnings and Precautions (including
the Serious Warnings and Precautions Box), and Consumer Information sections of the Canadian Product Monographs for all bacitracin for injection products. These updates will strengthen statements regarding the risk of nephrotoxicity, including kidney failure, and include information about serious hypersensitivity, including allergic contact dermatitis and/or anaphylaxis, in patients exposed to bacitracin.
Health Canada will also work with the manufacturers of bacitracin for injection products to collect information on utilization of these products and physician awareness of these risks in Canada. After reviewing this information, Health Canada will determine if further measures are needed to mitigate the risks.